R
Ryan P. Goepfert
Researcher at University of Texas MD Anderson Cancer Center
Publications - 74
Citations - 1221
Ryan P. Goepfert is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 15, co-authored 49 publications receiving 613 citations. Previous affiliations of Ryan P. Goepfert include University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
Jennifer Wang,Mark Zafereo,Ramona Dadu,Renata Ferrarotto,Naifa L. Busaidy,Charles Lu,Salmaan Ahmed,Maria Gule-Monroe,Michelle D. Williams,Erich M. Sturgis,Ryan P. Goepfert,Neil D. Gross,Stephen Y. Lai,Gary Brandon Gunn,Jack Phan,David I. Rosenthal,Clifton D. Fuller,William H. Morrison,Priyanka C. Iyer,Maria E. Cabanillas +19 more
TL;DR: The first series in the literature of BRAFV600E-mutated ATC patients with locoregionally advanced disease treated with DT followed by surgical resection is reported, demonstrating feasibility of complete resection, decreased need for tracheostomy, high pathologic response rates, and durable Locoregional control with symptom amelioration.
Journal ArticleDOI
Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019
Anastasios Maniakas,Ramona Dadu,Naifa L. Busaidy,Jennifer Wang,Renata Ferrarotto,Charles Lu,Michelle D. Williams,G. Brandon Gunn,Marie Claude Hofmann,Gilbert J. Cote,Jared Sperling,Neil D. Gross,Erich M. Sturgis,Ryan P. Goepfert,Stephen Y. Lai,Maria E. Cabanillas,Mark Zafereo +16 more
TL;DR: In this large single-institution cohort study spanning nearly 20 years, changes in patient management appear to be associated with significant increase in survival, progressively being replaced by molecular-based personalized therapies, with integration of multidisciplinary therapies including surgery and radiation therapy.
Journal ArticleDOI
Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions
Samantha Tam,Mongkol Boonsripitayanon,Mongkol Boonsripitayanon,Moran Amit,Bryan Fellman,Yisheng Li,Naifa L. Busaidy,Maria E. Cabanillas,Ramona Dadu,Steve Sherman,Steven G. Waguespack,Michelle D. Williams,Ryan P. Goepfert,Neil D. Gross,Nancy D. Perrier,Erich M. Sturgis,Mark Zafereo +16 more
TL;DR: The AJCC eighth edition is similar to the seventh edition in disease-specific survival prediction and potential modifications that may improve disease- specific survival prediction in future renditions include reconsideration of T3b tumor category and upstaging classification of patients <55 years of age with distant metastases.
Journal ArticleDOI
Complications, hospital length of stay, and readmission after total laryngectomy
Ryan P. Goepfert,Katherine A. Hutcheson,Jan S. Lewin,Neha G. Desai,Mark Zafereo,Amy C. Hessel,Carol M. Lewis,Randal S. Weber,Neil D. Gross +8 more
TL;DR: The purpose of this study was to describe the 30‐day incidence of complications after total laryngectomy in a high‐volume institution and their impact on the hospital length of stay (LOS) and readmission rates.
Journal ArticleDOI
Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results.
Renata Ferrarotto,Diana Bell,Maria Laura Rubin,Katherine A. Hutcheson,Jason M. Johnson,Ryan P. Goepfert,Jack Phan,Yasir Elamin,Danice Torman,Carla L. Warneke,Amy C. Hessel,Adam S. Garden,Jeffrey N. Myers,Faye M. Johnson,J. Jack Lee,Andrew G. Sikora,Maura L. Gillison,Bonnie S. Glisson,Neil D. Gross +18 more
TL;DR: Durvalumab + tremelimumab did not increase CD8+TIL density more than durvalsumab alone did, and the observed safety and activity support further investigation of neoadjuvant checkpoint inhibitor for OPC.